Sort
35,931 grants matching “parkinsons”
NINDS Office of the Clinical Director
$10,854,750Avindra Nath · National Institute Of Neurological Disorders And Stroke · ZID · FY2016 · NS
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
$10,764,669Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2021 · AG
NINDS Office of the Clinical Director
$10,720,370Avindra Nath · National Institute Of Neurological Disorders And Stroke · ZID · FY2015 · NS
Prevention of Fractures in Patients with Parkinson's Disease
$10,488,462Steven R Cummings · California Pacific Med Ctr Res Institute · R01 · FY2020 · AG
MOLECULAR MECHANISMS IN THE CO-MORBIDITY OF DEPRESSION, SCHIZOPHRENIA AND ANXIETY AND THEIR RELEVANCE TO PARKINSON'S DISEASE
$10,423,433Intra-Cellular Therapies, Inc. · · FY2008 · Department of the Army
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
$10,257,187Tatiana M. Foroud · Indiana University Indianapolis · U24 · FY2023 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
$10,254,288Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2022 · AG
NEW ENGLAND REGIONAL PRIMATE RESEARCH CENTER
$9,689,353Harvard University (Medical School) · P51 · FY2002 · RR
SysBio FAIRplex: a FAIR PLatform for EXploration of Systems Biology
$9,151,568Lisa S Lehmann · Verily Life Sciences Llc · OT2 · FY2025 · OD
THE MOLECULAR BASIS OF SELECTIVE DOPAMINERGIC CELL LOSS IN PARKINSON'S DISEASE AND PD RELATED DEPRESSION
$8,872,500Rockefeller University · · FY2009 · Department of Defense
Prevention of Fractures in Patients with Parkinson's Disease
$8,842,229Steven R Cummings · California Pacific Med Ctr Res Institute · R01 · FY2018 · AG
NEW ENGLAND REGIONAL PRIMATE RESEARCH CENTER
$8,742,353Harvard University (Medical School) · P51 · FY2001 · RR
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
$8,479,107Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2023 · AG
NEW ENGLAND REGIONAL PRIMATE RESEARCH CENTER
$8,220,317Harvard University (Medical School) · P51 · FY2000 · RR
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
$8,066,994John Alam · Eip Pharma, Inc. · R01 · FY2024 · AG
A National, Theranostic Cyclotron Resource to Drive Fundamental and Translational Medical Science
$8,000,000Robert N Golden · University Of Wisconsin-Madison · C06 · FY2023 · OD
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
$7,732,841Yo-El S Ju · Washington University · U19 · FY2021 · AG
Alzheimer's Gut Microbiome Project
$7,690,237Rima F Kaddurah-Daouk · Duke University · U19 · FY2023 · AG
University of Miami Federated Biorepository Facility to Advance Biomedical Research
$7,600,000Jacob L McCauley · University Of Miami School Of Medicine · C06 · FY2020 · OD
NINDS Office of the Clinical Director
$7,592,691Avindra Nath · National Institute Of Neurological Disorders And Stroke · ZID · FY2013 · NS
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
$7,226,355Daniel M Corcos · Northwestern University At Chicago · U01 · FY2023 · NS
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
$7,159,125Daniel M Corcos · Northwestern University At Chicago · U01 · FY2020 · NS
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
$7,100,969Yo-El S Ju · Washington University · U19 · FY2023 · AG
Dysfunctional lipid metabolism and peroxidation in chronic pain and neurodegeneration
$7,042,784Christopher Ramsden · National Institute On Aging · ZIA · FY2022 · AG
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
$7,016,272Yo-El S Ju · Washington University · U19 · FY2022 · AG